Mene Pangalos (AstraZeneca via YouTube)
October 11, 2021 07:12 AM EDT
R&D
Coronavirus

Af­ter fil­ing for au­tho­riza­tion of its Covid-19 an­ti­body as a pro­phy­lac­tic, As­traZeneca pulls out new da­ta in the treat­ment set­ting

Nicole DeFeudis

Editor

Less than a week af­ter As­traZeneca made its pitch to the FDA for emer­gency use of its mon­o­clon­al an­ti­body com­bo for Covid-19 pro­phy­lax­is, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times